The fact, that the intensity of PDGFRβ immunostaining in tumor cells was decreased in recurrences after denosumab treatment (Table 2; Figure 3) confirms the causing role of denosumab regarding PDGFRβ overexpression however, the precise mechanism is not known. This evidence concerns the gene PDGFRB and neoplasm.